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Systemic sclerosis (SSc) is a multisystem autoimmune disease: characterised from the
clinical side by progressive vasculopathy and fibrosis of the skin and different organs
and from the biochemical side by fibroblast deregulation with excessive production
of collagen and increased expression of nicotinamide adenine dinucleotide phosphate
oxidase 4 (NOX4). The latter contributes to an overproduction of reactive oxygen
species that via an autocrine loop maintains NOX4 in a state of activation. Reactive
oxygen and nitrogen species are implicated in the origin and perpetuation of several
clinical manifestations of SSc having vascular damage in common; attempts to dampen
oxidative and nitrative stress via different agents with antioxidant properties have
not translated into sustained clinical benefit. Objective of this narrative review is to
describe the origin and clinical implications of oxidative and nitrative stress in SSc,
with particular focus on the central role of NOX4 and its interactions, to re-evaluate
the antioxidant approaches so far employed to limit disease progression, to appraise the
complexity of antioxidant treatment and to touch on novel pathways elements of which
may represent specific treatment targets in the not so distant future.
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Introduction
Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by a
progressive non inflammatory vasculopathy with intimal hyperplasia affecting small
and large arteries [1] and by excessive production of collagen, fibronectin and
other matrix proteins which accumulate in the skin and internal organs, resulting in
fibrosis[2]. Free radical production is enhanced in SSc in relation to some clinical
manifestations as indicated in the following paragraphs. [3] While the review focuses
on the interplay between reactive oxygen species (ROS) generated by NOX and TGF-
beta, inflammasome and Nrf2 in the pathogenesis of fibrosis, we must touch on how the
immune system is affected by ROS in SSc.
Notes on Oxidative/Nitrative Stress and Immunity in Systemic Sclerosis
Oxidative stress is a measure of the prevailing levels of reactive oxygen species (ROS) in
biological systems determined by the relative rates of their formation and their removal
by plasma and cellular repair mechanisms [3]. In given micro-environments excess ROS








attack on membrane and/or lipoprotein lipids in a process called lipid peroxidation[4].
Nitric oxide (NO•) generated from arginine by the action of nitric oxide
synthases (NOS) regulates several biological processes including vasomotor tone.
Upon reaction with superoxide anion (O2•-), NO• forms peroxynitrite (ONOO-), which
interacts with CO2 to form nitrosoperoxocarbonate (ONOOCO2-). Aromatic amino
acyl (tryptophanyl, tyrosyl, phenylalanyl), cysteinyl and methionyl residues of proteins
are sensitive to modification by different forms of reactive nitrogen species (RNS),
depending upon the availability of CO2 and pH [3]. ONOO- is not only responsible for
the nitration of tyrosyl residues in proteins [5] but also for the formation of nitro-fatty
acids that may modulate metabolic- and anti-inflammatory pathways [6,7] 
 Oxidative stress may lead to cell/tissue damage by several mechanisms: by the oxidative modification of cell
macromolecules (DNA, proteins, lipids) that may occur by direct metal-catalyzed oxidation of amino acyl side chains and by
the formation of covalent adducts of the products of carbohydrate oxidation, advanced glycoxidation end products (AGE),
with DNA and proteins of crucial importance for cell viability. Auto-fluorescence of SSc skin reveals the presence of AGE
in relation to carotid radial pulse wave velocity and capillary flow percentage change during occlusion[8].
Moreover, the peroxidation of polyunsaturated fatty acids in phosphatidylcholine and
other phospholipids in cell membranes and in low density lipoprotein yield 1) γ-
hydroxy-alkenals generically called ALE that include acrolein, malonyldialdehyde and
2) an α,β-unsaturated hydroxyalkenal called and 4-hydroxy-2-nonenal (4-HNE) that
may form adducts with cysteine,lysine and histidine residues inducing post-translational
modifications in those proteins bearing such residues (5) and 2)a family of cyclic
molecules called isoprostanes, generated independently of cyclooxygenase, that are
sensitive and specific markers of oxidative stress and that have powerful vasoactive
properties [3]. 
 The engagement of oxidation-specific epitopes (OSE), including AGE/ALEs and
relevant adducts with DNA and proteins to scavenger receptors including RAGE induce
the activation of NF-#B [10] in endothelial cells, macrophages and dendritic cells








stimulation in SSc is highlighted by the report concerning the secretion of alarmins
(S100A8 and S100A9) from monocytes and neutrophils that bind to TLR4 and RAGE,
thereby recruiting and activating leukocytes into inflamed tissues[9].
The oxidative modification of self-epitopes with the consequent sensitization to
mixed self/non-self neoepitopes and the breaking of immunological tolerance to
their native counterparts, leads to immuno-mediated cell and tissue damage and the
appearance of autoantibodies. Various pro-oxidative agents (bleomicin, superoxide
anions, hydroxyl radicals, hypochlorous acid and peroxynitrite) injected in immune
deficient mice induced the development of serum anti-centromeric protein-B and anti-
DNA topoisomerase 1 autoantibodies. On the other hand, sera of oxidatively treated
mice (hypochlorite or hydroxyl radical) and of patients with diffuse SSc contained
high levels of ALE that triggered endothelial production of H2O2 and fibroblast
hyperproliferation[9].
Nicotinamide Adenine Dinucleotide Phosphate Oxidase in Systemic Sclerosis
The main source of ROS in the organism is the NOX family, composed of five different
NOX isoforms. NOX enzymes are characterized by six transmembrane domains and
two cytosolic domains respectively for NADPH and for flavin adenine dinucleotide[10].
NOX reduces molecular oxygen, forming superoxide anion O2•- and hydrogen peroxide
(H202), using NADPH as an electron donor that is transferred first to the FAD and then
to a heme group. Of the different NOX isoforms, NOX4 is particularly relevant to SSc:
1) though present on the surface of fibroblasts, vascular smooth muscles cells (VSMC)
 and endothelial cells (EC)[11]NOX4 is constitutively expressed on dermal fibroblast
[12] as it lacks cytosolic regulatory subunits, and therefore depends almost exclusively
on the amount of p22phox expressed on the cellular membrane[13]; 2) NOX4 does
not generate O2•- but almost exclusively H2O2; the latter does not react with NO• to
yield ONOO-[14]. Other cell types produce enhanced of ROS in SSc such as circulating








Nicotinamide Adenine Dinucleotide Phosphate Oxidase and Toll Like Receptors
Toll-like receptors (TLR) are a family of pattern recognition receptors (PRR) that sense
invading pathogens or endogenous damage signals and once stimulated initiate the
innate and adaptive immune response. Damage associated molecular patterns (DAMP)
appearing during the course of oxidation and nitration including post-translational
modification of certain connective tissue proteins and heat shock proteins also stimulate
TLR[17,18]. The intracellular signalling triggered by TLR activation is mediated by
the cytoplasmic adaptor molecule, MyD88 and by the serine/threonine kinases of the
IL-1R–associated kinase family, resulting in translocation of NF-κB to the nucleus and
synthesis of type I interferons and inflammatory cytokines[19]. TLR4 is a better sensor
for oxidative stress than other TLRs[20]. Interestingly, TLR4 and its co-receptors, MD2
and CD14, are over-expressed in affected skin from patients with diffuse cutaneous
SSc; the same study demonstrated in a mouse model that chronic TLR4 stimulation
is associated with increased expression of the TGF-β gene[21]. Others have also
demonstrated overexpression of TLR9 (an endosomal TLR) in the skin of SSc patients
of SSc mice in parallel with overexpression of TGF-β[22]. Conversely in vitro studies
show that TGF-β stimulated the expression of NOX4 both in normal dermal and in
SSc dermal fibroblasts via the PKC-δ and the Smad2/3 pathways[23] and that TGF-
β increases the expression of NOX4 in normal human lung fibroblasts[24].
Nicotinamide Adenine Dinucleotide Phosphate Oxidase and Inflammasomes
The inflammasome is a multiprotein oligomer that promotes the maturation and
secretion of pro-inflammatory cytokines involved in the inflammatory response; the
phagocyte inflammasome NLRP3 requires a two step signal for its activation: a priming
transcriptional step that involves NF-κB pre-activation by TLR2, TLR3, TLR4, and
TLR7 and a post-translational step that allows the oligomerization of the inflammasome
components followed by the maturation and secretion of IL-1β[25]. ROS participates








post-translational step[26]. ROS of NOX origin are critical for NLRP3 inflammasome
activation though mitochondrial ROS are also relevant[27].
The inflammasome is involved in the pathogenesis of SSc: a clinical study reported
over-expression of NLRP3 in affected skin of SSc patients compared to healthy
individuals: NLRP3, caspase-1, IL-1β, IL-18 and (endothelin-1) ET-1 were over-
expressed in affected skin of limited and diffuse SSc whereas limited SSc patients
showed a significant increase in eNOS, iNOS and TGF-β. The expression of NLRP3,
IL-1β, IL-18 and ET-1 correlated with dermal fibrosis in limited SSc[28]. In vitro studies
on SSc fibroblasts show that inflammasome activation favoured the expression of 40
genes involved in the synthesis of signalling. Moreover inhibition of caspase-1 in dermal
and lung SSc fibroblasts abrogated the secretion of collagens, IL-1β, and IL-18[29]. A
definitive proof for inflammasome involvement in fibrosis comes from the mouse model
of bleomycin-induced skin fibrosis where NLRP (-/-) mice failed to develop fibrosis
after bleomicin exposure[30]
Nicotinamide Adenine Dinucleotide Phosphate Oxidase & Antioxidant Responsive
Elements
The activity of NOX4 is also closely related to that of nuclear erythroid-derived factor-2
(Nrf2), the most important nuclear transcriptional factor involved in the expression of
genes coding for the synthesis of antioxidant enzymes[31]. In fact, Nrf2, interacting
with the Maf protein, binds the antioxidant responsive elements (AREs) in proximity of
the promoters of the genes coding for glutathione (GSH) biosynthesis and regeneration
(glutamate-cysteine ligase), for the thioredoxin system (eg thioredoxin reductase), for
the detoxification of ROS (eg NADPH quinone oxidoreductase-1) and for heme and
iron metabolism (eg heme oxygenase-1)[32]. This cross-talk is fundamental to restore
the oxidative-redox balance upset by excessive NOX4 generated ROS: the protective
role of NOX4 on the cardiovascular system[33] is due to the ability to promote growth,
proliferation and migration of endothelial cells[34]. In this scenario, NOX4 producing








NO• that restores endothelial and vascular function[35]. Moreover, thanks to its ability
to react with cysteine residues forming disulfide bridges, H2O2 is an important mediator
for many transcription factors and enzymes involved in the regulation of oxidative
stress[14].
Nicotinamide Adenine Dinucleotide Phosphate Oxidase and Fibrogenesis
Several fibrogenic cytokines such as TGF-β, platelet-derived growth factor (PDGF) and
angiotensin II (Ang II) induce the expression of NOX4 in various cell lines enhancing
thus the production of ROS. 
The TGF-β induced NOX4 expression through the Smad 2/3 and the phosphoinositide3-
kinase (PI3K) pathways[36] is particularly relevant at the pulmonary level: hypoxia
stimulates the release of TGF β from epithelial cells that, fibrosis aside, stimulates
threefold the expression of NOX4 on EC and VSMC favoring thus the transformation
of VSMC into myofibroblasts[37]; this causes a severe structural remodeling the intima
of the pulmonary vessels[38] that leads to pulmonary hypertension, one of the lethal
complications of SSc. 
Platelet, macrophage and fibroblast derived PDGF[39] synergizes with TGF-β: in fact
PDGF increases the production and mediates some of the effects of TGF-β, whereas
TGF-β stimulates PGDF in a positive feedback loop[40]. The intimal hyperplasia
characteristic of the early stages of SSc is associated with an over expression of
PDGF receptor (PDGFR) in EC and VSMC[41] that behaves as an autoantigen against
which activating autoantibodies can be formed[42]. Upon activation, PDGFRs trigger
a Ras, ERK1/2 and PI3K dependent intracellular pathway that stimulates NOX4 to
produce H2O2 which in turn activates fibroblasts resulting in further extracellular
matrix deposition[12,43]. 
AngII is a peptide that regulates vasomotor tone: its precursor angiotensinogen is
produced by the liver and is subsequently transformed into AngII through cleavage
first by the renin and subsequently by the angiotensin converting enzyme. Increased








1 receptor Ang II activates NOX4 which produces H2O2 and induces the decoupling of
the eNOS, stimulates the production of TGF-β and activates PKC which by means of
ERK1/2 induces the deposition of proteins of the extracellular matrix with consequent
fibrosis[45]. 
Oxidative and Nitrative Stress markers in Systemic Sclerosis
A recent meta-analysis including 47 articles and 12 oxidative stress markers confirmed
an oxidant/antioxidant imbalance in SSc:oxidative markers such as NO•, asymmetric
dimethyl arginine (ADMA), malondialdehyde (MDA), carbonyls and ROOH were
higher in SSc than in control groups whereas the antioxidant vitamins E and C, and
thiols were lower alongside a decreased enzymatic activity of superoxide dismutase
(SOD) and catalase (CAT)[46]. Another meta-analysis confirmed overproduction of
isoprostanes in SSc[47]. 
More recently an imbalance of the vanin/pantetheinase system emerged as a contributor
to oxidative stress in SSc; the hydrolysis of vasculoprotective pantethine generates
pantothenic acid that has profibrotic effects and cysteamine (then cystamine) that
has pro-oxidant effects[48]. In turn cystamine directly[49] and indirectly via the
Nfr2 pathway[50] inhibits directly γ-glutamyl synthetase, the rate-limiting enzyme of
glutathione (GSH) synthesis that has strong free radical scavenging effects. Diffuse
cutaneous (dcSSc) patients overexpress vanin-1 in the skin and the circulatory system,
and display elevated levels of serum pantothenic acid in relation to disease severity [51].
Micro/macrovascular Disease in Systemic Sclerosis: Functional Studies
The initial functional and structural hallmarks of microvasculature changes in SSc
are Raynaud’s phenomenon (RP) and the morphological abnormalities seen at
capillaroscopy [52]. Endothelial dysfunctionmay be present at this early stage, whereby








arterial vasodilation alongside a pro-inflammatory and pro-thrombotic state[53]. A
systematic review and meta-analysis on 7 studies and 283 SSc patients dealing with
functional vascular measurements revealed impaired flow mediated dilation (FMD)
with wide heterogeneity[54] though one study did not favour the impairment. A later
meta-analysis including 35 studies and 1292 patients came to similar conclusions though
4 studies did not favour the association. On the other hand nitroglycerine mediated
vasodilatation was not affected[55]. Microvascular involvement underlies subclinical
cardiac disease: a study on 19 asymptomatic SSc patients revealed decreased coronary
flow reserve (CFR) compared to controls (p<0.001); CRF was lower in dcSSc than in
the limited cutaneous SSc patients (lcSSc) (p=0.05); interestingly CRF was inversely
correlated with the time of onset of RP[56]. Functional microvascular impairment may
be simultaneously present with functional macrovascular impairment[57] but the recent
meta-analysis onfive studies concluded that ankle brachial index did not discriminate
SSc from healthy controls [55].
Micro/macrovascular Disease in Systemic Sclerosis: Morphological Studies
According to different methodologies the prevalence of macrovascular involvement
can be as high as 58% [58]. A systematic review and meta-analysis on atherosclerosis
measured as intima media thickness of carotid arteries on 14 studies including 666 SSc
patients revealed greater intima media thickness with wide heterogeneity [54]. The same
systematic review concluded that sub-clinical atherosclerosis was present in specific
districts such as the renal, radial and ulnar arteries [54] with the latter two leading to
ischaemia, ulceration or amputation of fingers [59-61]. 
A population based study calculated the hazard ratio (HR) for developing acute
myocardial infarction at 3.49, the HR being higher at 8.95 within the first year of SSc
diagnosis [62] whereas a later study identified SSc as an independent risk factor for acute








predilection for small coronary arteries or arterioles present in 17% of SSc against 2%
of controls (P<0.01)[64]; this matches the data of a very recent study in which SSc
patients had lower myocardial perfusion during adenosine stress compared to controls
(p=0.008) implying microvascular myocardial disease[65].
Oxidative Stress and Vascular Manifestations in Systemic Sclerosis
As mentioned previously ROS and more specifically isoprostanes are overproduced
in SSc and bear major clinical relevance [66]: 1) isoprostanes inversely correlated
with post-occlusion hyperemia, expressed either as raw data (p = 0.007) or as
an increase compared to baseline (p = 0.04) whereas endothelium-independent
response did not change [67]; 2) urinary isoprostane strongly correlated with nail
fold morphological capillaroscopic pattern (p=0.002) and lung involvement (p=0.003),
showing increasing levels with the progression of pulmonary severity [68]; 3) similarly
serum isoprostanes correlated negatively with pulmonary function (percentage vital
capacity and diffusion capacity for carbon monoxide) and positively with renal vascular
damage assessed by colour flow Doppler ultrasonography [69]. Among other less
specific oxidative stress markers,plasma hydroperoxides correlated with the semi-
quantitative capillaroscopy rating score (p < 0.05) [70].
Nitrative Stress and Vascular Manifestations in Systemic Sclerosis
SSc patients also show overproduction of nitrate [71,72] in relation to markers of
endothelial damage and disease activity [72]; dcSSc patients display higher plasma
concentration of crude plasma NT than patients with lcSSc, in relation to the severity and
the duration of the disease; moreover NT staining is increased in skin biopsy sections
from dcSSc compared to lcSSc [73]. At variance another study did not detect NT
differences between dcSSc and lcSSc disease, though in the whole SSc population NT
levels correlated inversely with the carbon monoxide diffusion capacity (p < 0.02) [74].
To gain further insight in on the nitrative stress pathway, histologically graded skin







3) and eight healthy controls were reacted with antibodies against eNOS and inducible
NOS (iNOS) and NT. The degree of staining was assessed using a semi-quantitative
system and a staining score was developed for the endothelial cells (EC) of different
vessel types in different areas of dermis at all grades. In biopsies from patients with
SSc, superficial microvessel ECs showed a peak of eNOS expression in grade 1 skin
which fell as the grade increased. By contrast, iNOS staining increased with the grade
of skin lesion, a pattern paralleled by endothelial NT detection. These findings suggest
that at some point during the progression of the skin lesions, dermal ECs undergo a
metabolic switch from constitutional expression of eNOS to cytokine activation of iNOS
that, in the presence of adequate substrate availability (arginine) releases up to 1000
fold more NO• than eNOS; this excess NO• reacts with O2•- forming more ONOO- that
my nitrate skin proteins as well as contributing to EC malfunction [75]. This has to be
reconciled with the notion whereby several stimuli failed to activate iNOS in human
EC[76] whereas iNOS is truly inducible in murine ECs [77]
Human interventional Studies with Agents bearing Antioxidant Properties
With the knowledge that SSc patients overproduce ROS in relation to specific clinical
features, several authors undertook interventional trials with different agents bearing
antioxidant properties as indicated below. 
Vitamin E and A: mechanisms of action
Vitamin E (α-tocopherol) is a lipid soluble membrane antioxidant that protects against
lipid peroxidation by scavenging free radicals and superoxide[78] though it may also
increase intracellular superoxide dismutase and catalase via NF-κB modulation[79]. Its
efficacy in SSc has been tested in isolation or in combination with various agents. 
Vitamin A (retinol) derives from -carotene, a polyunsaturated hydrocarbon present in
the hydrophobic domains of LDL, member of the large carotenoid family that includes








peroxyl radicals: this effect strongly depends on the O2 partial pressure and it is possibly
overcome by pro-oxidant toxic effects at the high O2 partial pressure in the lungs. As
a transcriptional modulator, Vitamin A (as all-trans-RA) regulates in a dose-dependent
manner collagen gene expression in fibroblasts from normal subjects and from SSc
patients[80].
Vitamin E and A in systemic sclerosis
A randomized, double-blind, placebo-controlled trial compared the efficacy of 500
or 1000 mg of vitamin E once daily versus placebo in SSc: after three weeks of
treatment neither dose of vitamin E had any effect on the clinical (blood flow variation
in response to cold) or the biochemical outcomes [81]. Vitamin E has been used
in combination with vitamin C (a water soluble and chain breaking antioxidant that
promotes the regeneration of vitamin E), beta-carotene (two molecules of dietary
vitamin A joined together), selenium (cofactor to several intracellular enzymes with
antioxidant activity: glutathione peroxidase, thioredoxin reductase and iodothyronine
deiodinases), and methionine in a placebo-controlled double-blind crossover study.
The efficacy of the above mentioned concoction, “BioAntox”, was evaluated on
the frequency and the duration of RP attacks, on the thermographic response to a
standard cold challenge and on free radical markers in lcSSc; after the 20-week study
period there was no effect on clinical outcomes despite an increase of the levels
of antioxidant molecules on active treatment[82]. In a further study vitamin E (800
UI/day) was paired with pentoxyphylline (800 mg/day) in a 24 week open-label
trial to examine their effect on a possible decrement of the modified Rodnan skin
score (from a baseline of at least 15 points), an improvement of ischemic ulcers and
laboratory parameters; after 16 weeks the average skin score had decreased from 25.7
to 18.7 and remained such at 24 weeks; however the intervention with two agents
limits our understanding of the effect of Vitamin E [83]. Finally, a randomized trial
compared intravenous cyclophosphamide (500mg/m2 of body surface area monthly)







vitamins without cyclophosphamide: after six months the skin thickening of SSc
patients receiving antioxidants with cyclophosphamide was significantly inferior than
that of SSc receiving cyclophosphamide alone but it is not clear how much of the benefit
can be ascribed to either vitamin [84]. The topical administration of vitamin E twice
weekly, in addition to a standard medication protocol, induced faster pain resolution and
healing of digital ulcers in 15 treated SSc patients compared to 12 untreated controls (n
= 12)[85]. 
With regards to carotenoids, protracted topical tretinoin resulted in considerable
improvement in mouth and facial skin tightening in few patients[86]; etretinate, a
lipophilic, aromatic retinoid induced a 75% skin score decrement in SSc patients at
0.5 mg/kg per day, in isolation (7 cases) or in combination with other drugs (systemic
corticosteroids, immunosuppressants, d-penicillamine, methotrexate, bucillamine and/
or UVA irradiation) (5 cases) compared to 19 SSc patients not receiving etretinate,
but only ointments and vasodilators (6 cases) or other drugs (corticosteroids,
immunosuppressant) (13 cases)[87]. 
N-Acetylcysteine: mechanism of action
Acetylation of the aminoacid L-cysteine yields N-Acetylcysteine (NAC), the direct
antioxidant activity of which resides within the thiol group; however, the scavenging
effect in vivo depends on the reaction rate of NAC towards the oxidants formed at any
given intracellular or extracellular site and on the relative concentrations of antioxidant
and oxidant present at any given moment. With this in mind NAC has reasonable direct
antioxidant activity against NO2, hypohalous acids deriving from peroxidases and HOX
but negligible activity against H2O2, O2•-, and ONOO-,[88]. On the other hand NAC
behaves as an indirect antioxidant by boosting the intracellular content and consequently
the natural antioxidant defence of GSH that has been depleted for any reason. GSH








elevated (mM) intracellular concentrations[89]. NAC achieves this as a precursor of
cystein, the rate-limiting factor in cellular GSH[90]. The latter is as a substrate or
cofactor for a large number of cellular antioxidant enzymes: glutathione reductase,
glutaredoxin, glutathione peroxidase, peroxiredoxin, glyoxalases 1 and 2, glutathione
transferase[91]. Given in acute or chronic regimens NAC significantly replenished the
GSH pool in certain organs such as liver, skin, lung, and brain, preventing the damaging
effects of GSH impoverishment on these organs. NAC has the ability to restore the
intracellular thiol pool that in turn regulates the redox state[92].
N-Acetylcysteine in systemic sclerosis
A parallel, double-blind, placebo-controlled, prospective study carried out on 22 SSc
failed to show any clinical response after 1-year of oral NAC (up to 10g/day) [93]; the
inefficacy of NAC via the oral route (1.8 g daily) on digital blood flow and RP was
confirmed in a short tem double-blind, placebo-controlled trial on 42 SSc patients [94].
Converselyone group has consistently shown the benefits of intravenous NAC (15 mg/
Kg/h for 5 consecutive hours every 14 days) in the medium term management of SSc:
in one open label study carried over 3 years they documented a reduction of attacks
and severity of RP and of digital ulcers [95], a reduction of the resistance index of the
renal arteries alongside an improvement of the diffusion capacity for carbon monoxide
[96,97]. 
Penicillamine: mechanism of action
Of the effects that PEN has on collagen metabolism [98] few were exploited in the
management of SSc: PEN interferes with collagen biosynthesis, with the formation
of intra and inter molecular cross links and accelerates collagen turnover [99-101].
Moreover, PEN seems to have also antioxidant proprieties: it is structurally similar to
the α-amino acid cysteine but with two methyl groups attached to the same α carbon as
the thiol group that can act as an electron donor scavenge free radicals in a way similar







would deplete the reduced form of PEN as the first line of antioxidant defence against
ROS. In turn PEN would lessen the reduced form of glutathione (GSH) because of its
lower redox potential and be converted to a GSSG adduct. Under normal circumstances,
the GSSG adduct is reduced back to GSH by the action of cellular anti-oxidative
enzymes including glutathione reductase and glutathione peroxidase[103].
Penicillaminein systemic sclerosis
Between 1966 and 1988 several uncontrolled studies, using different dosages and
duration of treatment, concluded that PEN decreased skin thickness in patients with
systemic sclerosis[104-107] These evidences led other authors to design studies with
with more representative samples and more reliable endpoints. The ambiguous results
obtained aroused a fervent debate at the beginning of the 2000s, causing various
controversies on this topic [108,109]. In fact the only one double blind, randomized,
prospective study, investigating the effect of low dose (125 mg every other day) and
high dose (822 mg daily) of PEN, failed to show any clinical improvement in systemic
sclerosis[110] whereas many other observational and retrospective studies [111-113]
demonstrated that PEN reduces skin sclerosis, slows new visceral organ involvement
and improves 5 years survival. In fact, at a median dose of 750 mg per day, PEN is
associated with a statistically significant reduction in skin, renal, cardiac and pulmonary
involvement and overall mortality [111-113]. Unfortunately 20% of patients on PEN
developed membranous glomerulopathy with proteinuria with a 40% mortality [114]
and many others developed several autoimmune disorders[115].
Probucol: mechanism of action
Probucol is a bis-phenol lipophilic lipid-lowering agent that inhibits oxidation of low-
density lipoproteins from which its antioxidant activity that was initially attributed








oxidation that is instead achieved by the two sulphur moieties of probucol[117].
Probucol increases the expression of HO1 gene and activity in balloon-injured
rabbit aorta and rabbit aortic smooth muscle cells[118]: the promoter region of
the HO1 gene contains multiple copies of ARE controlled by the redox-sensitive
transcription factor Nfr2[119]: the phenol moieties of probucol are involved in this
effect[120]. Moreover probucol inhibited lipopolysaccharide-induced nuclear NF-
кB activation in paw tissue as well as NF-кB activity in cultured macrophages
indicating that probucol may block the NF-кB transcriptional pathway[121].
Furthermore, probucol inhibits protein argininemethyltransferase I expression, increase
dimethylarginine dimethylaminohydrolase activity, reduce the asymmetric dymethil
arginine concentration and restore the activity of eNOS in cultured EC[122]whereas in
animal models it enhances catalase and glutathione peroxidase activities[123].
Probucol in systemic sclerosis
One trial compared the efficacy of probucol (500 mg/day) or nifedipine (20 mg/day) on
the frequency or severity of RP attacks in primary or SSc related RP over a 12 week
period: patients on probucol experienced less frequent and less severe attacks of RP
than those on nifedipine [124]. 
Statins: mechanism of action
Statins are cholesterol lowering drugs that inhibit the enzyme 3-hydroxy-3-
methylglutaryl-CoA (HMG-CoA) reductase, fundamental step in the synthesis of
endogenous cholesterol. Statins are pleiotropic drugs in that apart from lowering
cholesterol they have also anti-inflammatory, antioxidant, anti-fibrotic and anti-platelet
properties. These pleiotropic effects are due to their ability to suppress pro-oxidant
enzymes such as NOX, to induce the nitric endothelial oxide synthase (eNOS) and
enhance levels and activity of endogenous antioxidant systems.
Endothelial NOS generates NO• by converting L-arginine into L-citrulline in the
presence of nicotinamide adenine dinucleotide phosphate (NADPH) and other
cofactors such as calmodulin, flavin adenine dinucleotide, flavin mononucleotide








anti-inflammatory, anti-proliferative and antithrombotic activities. Statins regulate
eNOS expression through several mechanisms. One is the inhibition of mavelonate
formation, the precursor of isoprenoids such as geranyl-geranyl-pyrophosphate (GGPP)
and Farnesyl-pyrophosphate (FPP). The GGPP activates the Rho A pathway that
destabilizes the eNOS mRNA[126], and inhibits the PI3K/Akt pathway, preventing thus
the phosphorylation of eNOS[127]. FPP, through the sterol regulatory building protein
reduces the transcription of caveolin-1 and activates eNOS[128].
Statins have a dual antioxidants capacity: they can suppress pro-oxidant enzymes
and activate antioxidant ones. With regards to the former capacity, atorvastatin down
regulated NOX1 expression and Rac1 membrane translocation in VSMCs resulting in
reduced ROS generation[125,129]. In a reverse fashion, withdrawal of cerivastatin from
VSMCs in culture induced the translocation of Rac1 to the membrane, with a subsequent
activation of NOX complexes and increase in ROS production[130]. Moreover, porcine
coronary arteries exposed to high glucose levels generated increased ROS that may was
suppressed by statins through reduction of p22phox mRNA levels[131]. In the cellular
membrane, NOX oxidase co-localizes with ceramide and acid sphingomyelinase to
form membrane rafts; statin treatment prevents the oxidised low density lipoprotein
induced formation of membrane rafts consequently reducing ROS generation from
human coronary artery endothelial cells[132]. In a rat model, statin suppressed NOX
activity through a mevalonate-dependent prevention of Rac activation, favouring
increased NO bio-availability and improved endothelial function[133]. In humans,
short-term treatment with atorvastatin rapidly inhibits NOX activity hence ROS
generation in saphenous venous grafts from patients undergoing coronary artery bypass
independently of the lipid lowering effect of the drug[134].
With regards to stimulating anti-oxidant enzymes, simvastatin partially restored renal
levels of the three major cellular antioxidant defence systems (SOD, GSH-Px, and
catalase) in diabetic animals[135,136] whereas in rats chronically treated with the eNOS
inhibitor L-NAME statins improve endothelial function by increasing SOD levels[137].







down regulating the expression of NOX4 and increasing the expression of SOD[138].
Atorvastatin increase the gene expression and activity of catalase in aortic VSMCs from
rats and in senescent HUVECs[125].
Furthermore, by inhibiting pro-oxidant enzymes and restoring eNOS coupling, statins
act also at transcriptional level: in fact, reduction of ROS generation prevents ROS
induction of NFkB; in addition statins increase the levels of the inhibitor IkBα and
decrease those of IKK, reducing the binding capacity of NFkB that does not engage in
the transcription of genes coding for pro-inflammatory cytokines[139].
Statins in systemic sclerosis
Stemming from this evidence, several studies investigated the protective role of
statins in SSc and a recent meta-analysis determined that statins treatment is associated
with significant biochemical and clinical improvements[140]. All studies included in
the final analysis showed a significant reduction of Interleukin-6 (IL-6), E-selectin,
vascular endothelial growth factor (VEGF), endothelin 1, and basic fibroblast growth
factor[140-147] Only one study measured NO that significantly increased following
treatment with simvastatin at a dose of 20 mg daily for 12 weeks[140]. Four of the
studies in the meta-analysis evaluated flow mediated vasodilation. Of these, three
cohort studies showed a significant improvement in endothelium dependent dilatation
though the only randomized control trial present in the meta-analysis not revealed any
improvement in endothelium dependent and independent vasodilatation after 8 weeks of
treatment with 20 mg of Simvastatin. In all the studies considered in the meta-analysis,
no significant improvements was shown in regard of other vascular parameters, such
as endothelium independent vasodilatation, arterial stiffness, ankle/brachial index or
carotid intimal medial thickness.









Conditioned media from SSc patients and isoprostanes inhibited endothelial cell tube
formation in vitro, the equivalent of angiogenesis in vivo, via activation of the
thromboxane A2 receptor and the Rho-associated kinase pathways that suppresses
vascular endothelial growth factor (VEGF) activity. The addition of vitamin E increased
cell tube formation [148].
Edaravone
Edaravone is a phenolic compound used in neurology to limit hydroxyl radical-
dependent and radical-independent peroxidation of brain lipids [149]; it quenches ROS
generated from neutrophil NOX and by mitochondria[150]rather than by inhibiting
neutrophil function[151]. In animal models of ischemia-reperfusion edaravone
suppresses the oxidative/inflammatory response secondary to ROS [152]. In the tight
skin mouse and in the bleomycin-induced SSc mouse edavarone reduced skin and lung
fibrosis alongside the reduction of fibrogenic cytokines and ONOO [153].
Lipoic acid
Alpha-lipoic acid (LA) is a naturally occurring dithiol compound enzymatically
synthesized in mitochondria from octanoic acid[154]. From the free radical perspective,
in cells containing mitochondria, LA is reduced to dihydrolipoic acid (DHLA) via an
NADPH-dependent reaction with lipoamide dehydrogenase whereas in cells lacking
mitochondria LA is reduced to DHLA via thioredoxin reductase [155]. Two relevant
aspects of LA are that both its oxidized and reduced forms are powerful antioxidants and
being amphiphilic ad that LA exerts its antioxidant effects in the cytosol as well as in the
plasma membrane[156]. In particular LA scavenges hydroxyl radicals and hypochlorous
acid and prevents protein carbonyl formation but most importantly it neutralizes free








Another relevant aspect of LA is its ability to reduce the oxidized forms of other
antioxidants such as GSH, vitamin C and E. As an intracellular antioxidant, GSH buffers
the thiol redox state: this requires a steady intracellular level of GSH either by substrate
availability or by the transcriptional regulation of the GSH gene[159]. Accordingly LA
increases cysteine uptake[160] reducing thus the ratio of cystine to cysteine (as cysteine
is the rate-limiting substrate for this reaction) [161] and activates Nrf-2 that mediates
the gene expression and synthesis of GSH[159].
Moreover LA regenerates vitamin E either directly by reacting with
tocopheroxyl radical or indirectly by reducing dehydroascorbate, which in turn reduces
alpha tocopherol. LA also reduces ubiquinone to ubiquinol, an essential component of
the mitochondrial electron transport chain[158]. A stable availability of intracellular
GSH prevents the age related oxidation of the sulphur amino acids cysteine and
methionine, maintaining them in a reduced form[162] LA has regulatory effects on
gene transcription: apart its effect of Nrf-2, LA inhibits IκB degradation and NF-κB-
dependent gene expression independently of its antioxidant function[157,163]. Finally
because of its two thiol groups, LA chelates several divalent metal ions in vitro and
can form stable complexes with Fe2++ [164] minimising thus iron induced oxidative
stress[165]. We know thattotal plasma and dermal fibroblast thiols are reduced in SSc
[148]. 
In vitro experiments have shown that LA and its metabolite dihydrolipoic acid (DHLA)
behave as antioxidants in dermal fibroblasts in that they quench the production of
ONOO- that in turn is accompanied by a reduction of PDGFR phosophorilation and
consequently lower expression of Col I; the authors suggest that LA and DHLA may
act on redox-sensitive transcription factors that control the expression of phosphatases
though their data cannot be extrapolated to the in vivo scenario [166].
Pantethine
As mentioned earlier pantethine is a vasculoprotective compound made up of two








by the addition of cysteamine; the vanin/pantetheinase pathway [48] may hydrolyse
pantethine into pantothenic acid that is profibrotic and cysteamine that is pro-oxidant.
Over activation of the vanin-1/pantetheinase pathway occurs in wild-type BALB/c mice
with hypochlorous acid (HOCl)-induced SSc [167]. Pantethine administration restored
the production of gluthatione and decreased the generation of ONOO- in fibroblasts and
EC alongside a decrease in skin and lung fibrosis [167]. 
Asiatic acid
Asiatic acid is a pentacyclic triterpenoid extracted from Centella asiatica, a herbaceous
perennial plant from the family of Apiaceae: it inhibits TGF-1-induced collagen
expression in human keloid fibroblasts, via PPAR-gamma activation [168]. In the
hypochlorous acid-induced murine model of systemic sclerosis, asiatic acid alleviated
pulmonary fibrosis and slowed disease progression compared to untreated mice.
Moreover, trans-differentiation of fibroblasts into myofibroblasts was significantly
reduced in the lungs of SSc mice treated with asiatic acid[169]. 
Tanshinone IIA
Tanshinone IIA is a natural diterpene quinone with antioxidant and anti-inflammatory
properties, isolated from the root of Salvia miltiorrhiza. It exerted inhibitory effects on
IL-17-induced ERK phosphorylation and functional activation (proliferation, collagen
type I and III synthesis, and migration) of dermal vascular smooth muscle cells isolated
from SSc patients[170].
Crocetin
Crocetin is an apocarotenoid dicarboxylic acid extracted from Crocus flowers and
Gardenia jasminoides fruits. Crocetin inhibited the proliferation of normal and SSc
fibroblasts and the trans-differentiation of SSc fibroblasts into myofibroblasts; in the








skin and lung fibrosis in association with decreased levels of mRNAs for type 1 collagen
and endothelin-1 in skin and lung[171]. 
Epigallocatechin-3-gallate
Epigallocatechin-3-gallate (EGCG) is the ester of epigallocatechin and gallic acid
(trihydroxybenzoic acid), a type of phenolic acid. EGCG is a polyphenol found in
high content in the leaves of green tea and white tea. Orally administered EGCG is
poorly absorbed. EGCG down-regulates, in a dose-dependent manner, basal levels of
type I collagen and TGF--stimulated production of type I collagen, fibronectin and
connective tissue growth factor (CTGF) in fibroblasts isolated from normal subjects and
patients affected by SSc. More interestingly EGCG suppressed TGF--induced ROS
production in all fibroblasts and inhibited NF-B activation in response to TGF- or
PDGF-BB[172,173]. 
Curcumin
Curcumin is a phenolic diarylheptanoid deriving the spice turmeric (Curcuma longa).
Curcumin protected rats against lung fibrosis induced by bleomycin[174] and induced
apoptosis in scleroderma lung fibroblasts, but not in normal lung fibroblasts[175].
Curcumin acted via induction of the Nrf2/ARE pathway, increasing the expression of
intracellular detoxifying enzymes in fibroblasts[176]. Furthermore, curcumin exerted
a marked inhibitory activity on TGF- signaling in SSc fibroblasts, by counteracting
TGF--induced phosphorylation of Smad2, but not Smad3[177]. Unfortunately the
potential utility of curcumin as a therapeutic agent is limited by its chemical instability,







Appraising the Complexity of Antioxidant Treatment
Before considering treatment with antioxidant agents it must be appreciated that ROS
and RNS develop in different intracellular compartments within different cell types and
in different organs before occurring systemically [180]. From the previous paragraphs it
appears that intracellular NOX and extracellular TGF-β have reciprocal effects: NOX4
mediates TGF-β induced pro-fibrotic responses [181] whereas TGF-β specifically
increases NOX4 gene expression [182]. In keeping with the first pathway treatment with
small interfering RNA against NOX4 prevented the expression of TGF-β target genes
such as fibronectin, collagen I and connective tissue growth factor [142]; with regards to
the second pathway TGF-β upregulates NOX4 expression hence ROS via the classical
Smad2/3 and the PI3K intracellular pathways[183]. Moreover, intracellular ROS may
increase JNK and p38 activation aiding further the effect of TGF-β-induced signalling
[184] whereas extracellular ROS may directly convert inactive TGF-β to its active form,
a crucial step in TGF-β signalling [185]: in fact HNN, the major reactive aldehyde
formed during lipid peroxidation, when added to cultured macrophages up-regulates
the expression and release of TGF-β[186]. Finally TLR4 may be sense ROS[20] and
mediate NFkB activation via non-receptor tyrosine kinases[19] and via inflammasomes
[29]; ROS/RNS generated in the course of oxidation and inflammation may also induce
post-translational modifications in connective tissue proteins that in turn may act as
danger signals for TLR4 and further perpetuate the production of TGFβ hence of
fibrosis[18]. It remains to be ascertained whether these in vitro pathways are also active
in vivo. Apart from this complex interplay, antioxidant agents, including vitamins, react
with O2•- almost one billion times slower than NO•; this means that the reaction of O2•-









To restore or to increase the intracellular antioxidant environment seems an attractive
goal: unfortunately only a limited number of agents able to induce the transcription of
Nfr2 and enhance the synthesis of detoxifying enzymes. Amongst these curcumin [176]
probucol [118] and LA[159]seem suitable candidates. Curcumin however has limited
pharmaco dynamic and pharmaco kinetic properties [178,179], probucol has the added
benefit of suppressing NF-кB activation [121], whereas LA not only activates Nrf-2
[159], but increases cysteine uptake [160], maintains in reduced form other intracellular
antioxidants including vitamin E [159] and inhibits NF-κB-dependent gene expression
[144,150] making it an all-round and desirable antioxidant agent.
Targeting NAPDH oxidase
Silencing NOX4 with small inhibitory RNA improved bleomycin induced lung
fibrosis in the specific mouse model[187]; GKT-137831, a specific NOX1 and NOX4
inhibitor under clinical development[188] decreases CCN2 and α-SMA expression and
collagen gel interaction in SSc fibroblasts[189]. Azithromycin (AZM), apart from its
antibiotic activity, exerts antioxidant and antifibrotic properties in the bleomycin mouse
model of lung fibrosis[190]; in particular AZM degrades the proteasome activating
NOX4, preventing the TGFβ-induced myofibroblast differentiation and limiting lung
fibrosis[191]. Diphenyleneiodonium, a pan-Nox inhibitor, inhibited gene expression of
collagen type and fibronectin in human dermal fibroblasts and limited skin fibrosis and
myofibroblast activation in the bleomycin mouse model [192]. 
Outside SSc, atorvastatin and rosuvastatin have the capacity to inhibit the NOX
system [193,194]; in a mouse model of diabetes probucol downregulated NOX
expression[195] and in human renal proximal tubular epithelial cells it prevented
epithelial-mesenchymal transition [196] though the latter is debated[197]; it is
envisaged that probucol might have similar effect of SSc fibroblasts. LA may dampen
NOX activity either when being reduced [198] or via inhibition of the signalling








According to their lipophilic/hydrophilic nature, their dose and their route of
administration, antioxidants or agents with antioxidant properties may achieve in vivo
different plasma, tissue or intracellular level, and for each compartment the therapeutic
level may vary. On the other hand, one issue is to quench extracellular or intracellular
ROS/RNS, another is to target and switch off the genes and/or the enzymatic systems
producing them. In this respect statins, probucol and LA may have something new to
offer in the management of SSc. Knowledge of the cellular/sub-cellular localisation
of potential target enzymes, of the equilibrium constant of the biochemical reactions
involved and of the pharmacokinetics and pharmacodynamics of different antioxidants
are necessary pre-requisites for the planning of randomised clinical trials. These
might explore different doses and/or combinations of new and old antioxidants with
adequate follow-up, taking into account the timing of the intervention with regards
to disease duration, disease activity and organ involvement. The heterogeneity of the
SSc populations to be enrolled ought to be overcome by joining forces in multicenter
trials, possibly free from the influence of the pharmaceutical industry. It is envisaged
that an expert in free radical chemistry and biology should be included amongst the
team members to advice less savvy clinicians on the intricacies of redox biology in
vivo. The new information accrued over the last decade on ROS/RNS and their possible
manipulation at gene level makes this an interesting time for antioxidant intervention in
a disease such as SSc that still defies conventional treatments. 
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Abbreviations: df: diffuse; lc: limited; X: No effect; ↓: reduced; ↑increased; vWF: von Willebrand factor; RP: Raynaud phenomena;
MRSS: Modified Rodnan Skin Score; Cyp :cyclophosphamide; ESR: erythrocyte sedimentation rate; STPR: skin thickening
progression rate; MSDSS: Medsger Scleroderma Disease Severity Scale; DLCO: diffusing coeffcient for carbon monoxide ;FVC:
forced vital capacity; VC: vital capacity; TLC: total lung capacity; NAC:N-Acetylcysteine; HRTC: high resolution computed
tomography; RI: resistance index; NVC: Nailfoldvideocapillaroscopy; hsPCR: high sensitive protein C reactive, TBS:total body
surface. PEN: penicillamine. *This results was significant only for patients with early/active NVC pattern or MRSS<14. And not for
patients with more advanced disease. ^This dosage was considered ineffective and the authors used this group as a “placebo group”
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